SHARMA, V.; BAGRODIA, V.; KULSHRESHTRA, A. Enhancing hemophilia A management: emicizumab as a cost-effective adjunct to standard therapy for inhibitor patients. International Journal of Basic & Clinical Pharmacology, [S. l.], v. 13, n. 3, p. 395–397, 2024. DOI: 10.18203/2319-2003.ijbcp20241000. Disponível em: https://www.ijbcp.com/index.php/ijbcp/article/view/5579. Acesso em: 23 oct. 2025.